Benralizumab is effective in reducing asthma exacerbations: Results from the ZEPHYR 2 study

被引：0
|
作者：
Maselli, Diego J.
Carstens, Donna
Yang, Danni
Mu, Fan
Young, Joshua
Cook, Erin E.
Betts, Keith A.
Chung, Yen
机构：
来源：
ALLERGY AND ASTHMA PROCEEDINGS | 2022年 / 43卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：565 / 565
页数：1
相关论文
共 50 条
  • [1] BENRALIZUMAB IS EFFECTIVE IN REDUCING ASTHMA EXACERBATIONS: RESULTS FROM THE ZEPHYR 2 STUDY
    Maselli, D.
    Carstens, D.
    Yang, D.
    Mu, F.
    Young, J.
    Cook, E.
    Betts, K.
    Chung, Y.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S30 - S30
  • [2] Reduction in Asthma Exacerbations after Treatment with Benralizumab: Results from the ZEPHYR 2 Study
    Carstens, Donna
    Maselli, Diego
    Yang, Danni
    Mu, Fan
    Young, Joshua
    Cook, Erin
    Betts, Keith
    Chung, Yen
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB15 - AB15
  • [3] Real-World Effectiveness of Benralizumab on Asthma Exacerbations: Results from the ZEPHYR 1 Study
    Carstens, D. D.
    Katial, R.
    Young, J.
    Cook, E. E.
    Mu, F.
    Betts, K. A.
    Yang, D.
    Chung, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [4] Effectiveness of benralizumab in asthma patients with comorbid nasal polyps: Results from the ZEPHYR 2 study
    Carstens, Donna
    Genofre, Eduardo
    Emmanuel, Benjamin
    Mu, Fan
    Young, Joshua A.
    ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 565 - 565
  • [5] BENRALIZUMAB IS EFFECTIVE IN REDUCING COPD EXACERBATIONS IN PATIENTS WITH ASTHMA AND CONCOMITANT COPD
    Carstens, D.
    Maselli, D.
    Yang, D.
    Cook, E.
    Mu, F.
    Chen, J.
    Chung, Y.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S43 - S44
  • [6] REDUCTIONS IN EXACERBATIONS OF SEVERE ASTHMA PATIENTS TREATED WITH BENRALIZUMAB - ZEPHYR 3
    Carstens, D.
    Smith, J.
    Chung, Y.
    Pan, S.
    Barlows, T.
    Nepal, B.
    Barron, J.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S39 - S39
  • [7] ZEPHYR 3: Reductions in Exacerbations and Healthcare Resource Utilization in Patients with Severe Asthma Treated with Benralizumab
    Carstens, Donna
    Chung, Yen
    Pan, Suranne
    Barlows, Theodore
    Nepal, Bal
    Barron, John
    Smith, Joseph
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB18 - AB18
  • [8] Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2
    Carstens, Donna
    Maselli, Diego J.
    Mu, Fan
    Cook, Erin E.
    Yang, Danni
    Young, Joshua A.
    Betts, Keith A.
    Genofre, Eduardo
    Chung, Yen
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2023, 11 (07): : 2150 - +
  • [9] REAL-WORLD BENRALIZUMAB EFFECTIVENESS AMONG ASTHMA PATIENTS WITH COMORBID NASAL POLYPS: RESULTS FROM THE ZEPHYR2 STUDY
    Carstens, D.
    Genofre, E.
    Emmanuel, B.
    Mu, F.
    Yang, D.
    Cook, E.
    Betts, K.
    Chung, Y.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S37 - S37
  • [10] Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study
    Chung, Yen
    Katial, Rohit
    Mu, Fan
    Cook, Erin E.
    Young, Joshua
    Yang, Danni
    Betts, Keith A.
    Carstens, Donna D.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 128 (06) : 669 - +
12345